Skip to main content

Galante Joseph C's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) ยท filed Aug 19, 2022

Accession no.
0001209191-22-046896
Filed
Aug 19, 2022
Trade date
Jul 1-Aug 15, 2022
Filing delay
49 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 28 non-derivative transactions. Open-market purchases total $4.91K. It was filed 49 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Galante Joseph CCIK 0001632384Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 1, 2022Common StockPPurchaseAcquired+70$2.11+$147.748,836Direct
Jul 5, 2022Common StockPPurchaseAcquired+86$2.18+$187.4848,922Direct
Jul 6, 2022Common StockPPurchaseAcquired+86$2.11+$181.4649,008Direct
Jul 7, 2022Common StockPPurchaseAcquired+86$2.18+$187.4849,094Direct
Jul 8, 2022Common StockPPurchaseAcquired+86$2.19+$188.3449,180Direct
Jul 12, 2022Common StockPPurchaseAcquired+86$2.25+$193.549,266Direct
Jul 14, 2022Common StockPPurchaseAcquired+86$2.28+$196.0849,352Direct
Jul 15, 2022Common StockPPurchaseAcquired+86$2.23+$191.7849,438Direct
Jul 18, 2022Common StockPPurchaseAcquired+74$2.41+$178.3449,512Direct
Jul 19, 2022Common StockPPurchaseAcquired+74$2.47+$182.7849,586Direct
Jul 20, 2022Common StockPPurchaseAcquired+74$2.52+$186.4849,660Direct
Jul 21, 2022Common StockPPurchaseAcquired+74$2.54+$187.9649,734Direct
Jul 22, 2022Common StockPPurchaseAcquired+74$2.53+$187.2249,808Direct
Jul 25, 2022Common StockPPurchaseAcquired+74$2.48+$183.5249,882Direct
Jul 26, 2022Common StockPPurchaseAcquired+74$2.47+$182.7849,956Direct
Jul 27, 2022Common StockPPurchaseAcquired+60$2.36+$141.650,016Direct
Jul 28, 2022Common StockPPurchaseAcquired+74$2.28+$168.7250,090Direct
Jul 29, 2022Common StockPPurchaseAcquired+74$2.28+$168.7250,164Direct
Aug 1, 2022Common StockPPurchaseAcquired+74$2.34+$173.1650,238Direct
Aug 3, 2022Common StockPPurchaseAcquired+30$2.45+$73.550,268Direct
Aug 4, 2022Common StockPPurchaseAcquired+74$2.17+$160.5850,342Direct
Aug 5, 2022Common StockPPurchaseAcquired+74$2.12+$156.8850,416Direct
Aug 8, 2022Common StockPPurchaseAcquired+82$2.19+$179.5850,498Direct
Aug 9, 2022Common StockPPurchaseAcquired+82$2.19+$179.5850,580Direct
Aug 10, 2022Common StockPPurchaseAcquired+82$2.19+$179.5850,662Direct
Aug 11, 2022Common StockPPurchaseAcquired+82$2.46+$201.7250,744Direct
Aug 12, 2022Common StockPPurchaseAcquired+82$2.52+$206.6450,826Direct
Aug 15, 2022Common StockPPurchaseAcquired+65$2.45+$159.2550,891Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)